Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Holdings Lifted by Bank of New York Mellon Corp

Bank of New York Mellon Corp raised its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 8.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 120,954 shares of the company’s stock after purchasing an additional 8,974 shares during the quarter. Bank of New York Mellon Corp owned about 0.28% of Y-mAbs Therapeutics worth $1,461,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Ameritas Investment Partners Inc. grew its holdings in Y-mAbs Therapeutics by 39.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after buying an additional 1,056 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Y-mAbs Therapeutics by 66.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,390 shares of the company’s stock valued at $136,000 after buying an additional 3,340 shares during the period. Caxton Associates LP acquired a new stake in shares of Y-mAbs Therapeutics in the 1st quarter worth approximately $306,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Y-mAbs Therapeutics by 8.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock valued at $345,000 after acquiring an additional 1,657 shares in the last quarter. Finally, Boston Partners acquired a new position in shares of Y-mAbs Therapeutics during the first quarter valued at approximately $556,000. Institutional investors own 70.85% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on YMAB. Truist Financial initiated coverage on Y-mAbs Therapeutics in a research note on Friday, June 28th. They set a “buy” rating and a $21.00 target price for the company. Morgan Stanley decreased their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Wedbush restated an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Finally, Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Y-mAbs Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $21.14.

Y-mAbs Therapeutics Trading Up 3.2 %

Shares of NASDAQ YMAB opened at $14.00 on Friday. Y-mAbs Therapeutics, Inc. has a one year low of $4.69 and a one year high of $20.90. The business has a 50-day moving average price of $12.84 and a two-hundred day moving average price of $13.49. The firm has a market capitalization of $614.36 million, a PE ratio of -28.57 and a beta of 0.70.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The company had revenue of $22.80 million for the quarter, compared to analysts’ expectations of $23.09 million. During the same quarter in the prior year, the firm earned ($0.14) earnings per share. Research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.57 EPS for the current year.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the sale, the chief operating officer now directly owns 30,600 shares in the company, valued at $449,514. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Thomas Gad sold 65,000 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $13.47, for a total value of $875,550.00. Following the transaction, the insider now directly owns 97,681 shares of the company’s stock, valued at approximately $1,315,763.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the sale, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. The disclosure for this sale can be found here. In the last quarter, insiders sold 100,000 shares of company stock valued at $1,338,100. 21.50% of the stock is owned by corporate insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.